| SARS-CoV-2-positive (N = 94) | SARS-CoV-2-negative (N = 94) | Total | P value | |||||
---|---|---|---|---|---|---|---|---|---|
 | Age, mean yearsa | 35.71 ± 0.995 | 33.40 ± 0.932 | 34.56 ± 0.687 | 0.155 | ||||
Age groups | 15–24 | 16 | 7 | 23 | 0.088 | ||||
25–34 | 37 | 44 | 81 | ||||||
35–44 | 32 | 25 | 57 | ||||||
45–54 | 7 | 15 | 22 | ||||||
55–65 | 2 | 3 | 5 | ||||||
 | Total | 94 | 94 | 188 |  | ||||
 | Male, N (%) | 70 (74.46%) | 67 (71.27%) | 137 (72.87%) | (Male/Female ratio) 0.372 | ||||
 | Female, N (%) | 24 (25.53%) | 27 (28.72%) | 51 (27.12%) | |||||
symptoms | Cough | 24 (25.53%) | 40 (42.55%) | 64 (34.04%) | 0.027 | ||||
Fever | 20 (21.27%) | 40 (42.55%) | 60 (31.91%) | ||||||
Gastrointestinal | 23 (24.46%) | 17 (18.08%) | 40 (21.27%) | ||||||
Headache | 38 (40.42%) | 40 (42.55%) | 78 (41.48%) | ||||||
Sore Throat | 54 (57.44%) | 45 (47.87%) | 99 (52.65%) |